Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Vertex Appoints Charles Wagner as Chief Financial Officer
April 2, 2019 Off

Vertex Appoints Charles Wagner as Chief Financial Officer

By BusinessWire

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief…

X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors
April 2, 2019 Off

X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the…

Axcella Announces Patent Issuance for AXA™ Candidate AXA1125 Methods of Use
April 2, 2019 Off

Axcella Announces Patent Issuance for AXA™ Candidate AXA1125 Methods of Use

By BusinessWire

Patent issuance from Axcella’s broad Endogenous Metabolic Modulator (EMM) portfolio Claims cover methods of use of EMM compositions in liver…

Ocular Therapeutix™ Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
April 2, 2019 Off

Ocular Therapeutix™ Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery

By BusinessWire

PDUFA Target Action Date Set for November 10, 2019 BEDFORD, Mass.–(BUSINESS WIRE)—-Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused…

BergenBio shows bemcentinib’s potential to reverse tumour immunosuppression and therapy resistance
April 2, 2019 Off

BergenBio shows bemcentinib’s potential to reverse tumour immunosuppression and therapy resistance

By Dino Mustafić

BergenBio said Tuesday that preclinical data strengthen bemcentinib’s potential in reversing tumour-mediated immunosuppression and therapy resistance, ina presentation by its academic collaborators at the American Association for Cancer Research (AACR) Annual Meeting 2019.

April 2, 2019 Off

Worldwide Track and Trace Solutions Market: 2019 to 2024 – Growth in the Number of Packaging-related Product Recalls Augments Demand – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Global Track and Trace Solutions Market – Segmented by Product, Technology, Application, End-User, and Geography – Growth, Trends,…

April 2, 2019 Off

JMP Group Announces Addition of David Schechner to Healthcare Investment Banking Group

By BusinessWire

SAN FRANCISCO–(BUSINESS WIRE)–JMP Group LLC (NYSE: JMP), an investment banking and alternative asset management firm, announced today that David Schechner…

April 2, 2019 Off

Innovest Global Secures ‘Tier 1’ Manufacturer Buying Agreement, Will Add Several Million Dollars in 2019 Sales Volume

By BusinessWire

Contract with GAF, a new private label line, and a pending storefront acquisition highlight vertical integration and growth as Innovest…

April 2, 2019 Off

Advaxis, Inc. Announces Proposed Public Offering of Common Stock

By BusinessWire

PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of…

April 2, 2019 Off

Aro Biotherapeutics to Present Data on Lead Program, ABX900, at AACR

By BusinessWire

– Avidity Effect of a Single – Chain Multispecific Centyrin Results in Potent Inhibition of Tumors Expressing MET and EGFR…

Posts pagination

Previous 1 … 3,308 3,309 3,310 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine